Bora Pharmaceuticals Co., Ltd. a global leader in pharmaceutical manufacturing, and Corealis Pharma Inc., a leading early-phase Contract Development Manufacturing Organization (CDMO), have entered into a strategic alliance to provide end-to-end services for oral solid dose (OSD) development and manufacturing.

保瑞药业股份有限公司是全球制药制造的领导者，而科瑞利斯制药公司则是领先的早期合同开发制造组织 (CDMO)，双方已达成战略联盟，为口服固体剂量 (OSD) 的开发和制造提供端到端的服务。

The collaboration will simplify the drug development process and provide a more scalable pathway to commercialization via a single continuum..

该合作将简化药物开发过程，并通过单一连续体提供更可扩展的商业化途径。

Drug manufacturing has become increasingly complex, requiring specialized partners at every stage of development. Biotech and pharmaceutical innovators will now have access to both Bora’s global commercial infrastructure and Corealis’ deep expertise in formulation development and clinical-scale manufacturing.

药物制造变得日益复杂，需要在开发的每个阶段都有专门的合作伙伴。生物技术和制药创新者现在可以利用Bora的全球商业基础设施以及Corealis在配方开发和临床规模制造方面的深厚专业知识。

The collaboration creates a simple, more efficient route to bring new medicines to patients faster and more reliably..

该合作创建了一条更简单、更高效的途径，能够更快、更可靠地将新药带给患者。

“This collaboration is all about bridging capability and culture,” said J.D. Mowery, President of Bora’s CDMO division. “By combining Bora’s scale-up strength with Corealis’ early-phase expertise and leveraging the customer service and reliability focus of both organizations, we’re setting a new standard for CDMO collaboration.”.

“这次合作旨在连接能力和文化，”博拉公司CDMO部门总裁J.D. 莫里说。“通过结合博拉的规模化优势与科雷利斯的早期阶段专业知识，并利用两家公司以客户服务和可靠性为重点的优势，我们正在为CDMO合作树立新标准。”

Together, the companies will offer unified project management and aligned quality so that biotech and pharmaceutical companies can minimize outsourcing risk by working with an integrated CDMO alliance from discovery to commercial launch.

双方将提供统一的项目管理和一致的质量，使生物技术和制药公司能够通过与集成的CDMO联盟合作，从发现阶段到商业发布，最大限度地降低外包风险。

“Emerging biotechs often face timeline and flexibility challenges when scaling promising therapies from clinical to commercial lots,” said David Leroux-Petersen, CEO of Corealis Pharma. “The alliance with Bora provides our early-stage partners with a clear, fast, seamless, simple path to phase III manufacturing and commercial launch.”.

“新兴生物技术公司常常在将有前景的疗法从临床扩展到商业化生产时面临时间和灵活性的挑战，”Corealis Pharma首席执行官大卫·勒鲁-彼得森表示。“与Bora的联盟为我们的早期合作伙伴提供了一条清晰、快速、无缝且简单的III期生产和商业上市路径。”

Bora Pharmaceuticals is a premier international contract development and manufacturing organization (CDMO) specializing in formulation development, clinical and commercial manufacturing, and packaging of complex oral solid dose, liquid, semi-solid, biologic, and sterile injectable pharmaceutical products.

保瑞医药是一家国际顶级的合同开发和制造组织（CDMO），专注于配方开发、临床和商业生产，以及复杂口服固体制剂、液体、半固体、生物制品和无菌注射药物产品的包装。

From its world-class sites in North America and Asia, Bora delivers drug products with unparalleled quality to more than 100 markets around the world. Bora Pharmaceuticals Co., Ltd. is publicly traded on the Taiwan Stock Exchange (TWSE: 6472). For more information, visit www.boracdmo.com..

从其位于北美和亚洲的世界级工厂，博瑞医药向全球100多个市场提供无与伦比的高品质药品。博瑞制药有限公司（Bora Pharmaceuticals Co., Ltd.）在台湾证券交易所公开上市（TWSE: 6472）。欲了解更多信息，请访问 www.boracdmo.com。

Corealis Pharma Inc. is a privately held, GMP-compliant CDMO based in Laval, Québec, Canada. Specializing in oral solid dosage forms, Corealis provides customized formulation development, analytical, and manufacturing services for biopharmaceutical companies worldwide. Known for its flexibility, scientific expertise, and quality-driven approach, Corealis is a trusted partner in the development of complex drug products.

Corealis Pharma Inc. 是一家私人持有的、符合GMP标准的CDMO，总部位于加拿大魁北克省拉瓦尔。公司专注于口服固体剂型，为全球生物制药公司提供定制的配方开发、分析和生产服务。凭借其灵活性、科学专业知识以及以质量为导向的方法，Corealis 成为了复杂药物产品开发中值得信赖的合作伙伴。

Learn more at www.corealispharma.com..

欲了解更多信息，请访问 www.corealispharma.com。

Source: bora-corp.com

来源：bora-corp.com